Seroprevalence and associated factors of hepatitis B virus infection among HIV-positive adults attending an antiretroviral treatment clinic at Wolaita Sodo University Referral Hospital.
HIV
HIV-positive adults
co-infection
hepatitis B surface antigen
hepatitis B virus infection
highly active antiretroviral treatment regimens
Journal
Hepatic medicine : evidence and research
ISSN: 1179-1535
Titre abrégé: Hepat Med
Pays: New Zealand
ID NLM: 101544801
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
02
2019
accepted:
19
06
2019
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
1
10
2019
Statut:
epublish
Résumé
Hepatitis B virus infection (HBV) constitutes major public health problems in sub-Saharan Africa from different infections occuring in HIV positive patients. Ethiopia is a part of sub-Saharan Africa with 1.5% adult HIV prevalence, and also belongs to the intermediate to high HBV prevalence category. Hence, this study aimed to measure the seroprevalence and associated factors of HBV infection among HIV-positive adults attending an antiretroviral treatment (ART) clinic at Wolaita Sodo University Referral Hospital. An institution-based cross-sectional study was conducted from October 15 to December 10, 2017 using a systematic random sampling technique. After getting informed written consent, data were collected by a structured and interviewer-administered questionnaire. Venous blood was collected and centrifuged to separate serum. Hepatitis B surface antigen (HBsAg) was detected from serum using an advanced quality one-step rapid test kit. Data were entered into EpiData version 3.01 and exported to SPSS version 20. Summary statistics, bivariate analysis, and multivariate analyses were performed. The variables having significant association of A total of 442 study participants, 187 males and 255 females, were included in this study. Overall prevalence of HBsAg was 37 (8.4%). Family history of HBV (adjusted OR=8.83, 95% CI=2.56-30.49), multiple sexual partners (adjusted OR=7.08, 95% CI=2.29-21.9), and CD4 count <200 cells/μL (adjusted OR=15.34, 95% CI=4.77-49.3) were found to be significantly associated with HBsAg positivity. The prevalence of HBsAg in this study was high. Family history of HBV, multiple sexual partners, and CD4 count <200 cells/μL were independently associated with HBsAg positivity. Therefore, screening for HBV is recommended before initiation of ART in HIV patients and providing appropriate treatment for co-infection. Furthermore, accurate information on risk factors for HBV transmission should be provided.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B virus infection (HBV) constitutes major public health problems in sub-Saharan Africa from different infections occuring in HIV positive patients. Ethiopia is a part of sub-Saharan Africa with 1.5% adult HIV prevalence, and also belongs to the intermediate to high HBV prevalence category. Hence, this study aimed to measure the seroprevalence and associated factors of HBV infection among HIV-positive adults attending an antiretroviral treatment (ART) clinic at Wolaita Sodo University Referral Hospital.
METHODS
METHODS
An institution-based cross-sectional study was conducted from October 15 to December 10, 2017 using a systematic random sampling technique. After getting informed written consent, data were collected by a structured and interviewer-administered questionnaire. Venous blood was collected and centrifuged to separate serum. Hepatitis B surface antigen (HBsAg) was detected from serum using an advanced quality one-step rapid test kit. Data were entered into EpiData version 3.01 and exported to SPSS version 20. Summary statistics, bivariate analysis, and multivariate analyses were performed. The variables having significant association of
RESULTS
RESULTS
A total of 442 study participants, 187 males and 255 females, were included in this study. Overall prevalence of HBsAg was 37 (8.4%). Family history of HBV (adjusted OR=8.83, 95% CI=2.56-30.49), multiple sexual partners (adjusted OR=7.08, 95% CI=2.29-21.9), and CD4 count <200 cells/μL (adjusted OR=15.34, 95% CI=4.77-49.3) were found to be significantly associated with HBsAg positivity.
CONCLUSION
CONCLUSIONS
The prevalence of HBsAg in this study was high. Family history of HBV, multiple sexual partners, and CD4 count <200 cells/μL were independently associated with HBsAg positivity. Therefore, screening for HBV is recommended before initiation of ART in HIV patients and providing appropriate treatment for co-infection. Furthermore, accurate information on risk factors for HBV transmission should be provided.
Identifiants
pubmed: 31565003
doi: 10.2147/HMER.S206870
pii: 206870
pmc: PMC6735655
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137-147Informations de copyright
© 2019 Goa et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Ann Hepatol. 2006 Oct-Dec;5(4):276-80
pubmed: 17151581
Indian J Med Res. 2016 May;143(5):636-42
pubmed: 27488008
J Med Assoc Thai. 2015 Mar;98(3):226-31
pubmed: 25920291
Int J Infect Dis. 2014 Dec;29:65-70
pubmed: 25449238
Braz J Infect Dis. 2014 Sep-Oct;18(5):473-80
pubmed: 24662138
Mem Inst Oswaldo Cruz. 2017 Mar;112(3):209-213
pubmed: 28146158
Semin Liver Dis. 1991 May;11(2):73-83
pubmed: 1909458
Trop Doct. 2013 Jul;43(3):113-5
pubmed: 23800421
BMC Infect Dis. 2015 Jan 31;15:30
pubmed: 25637342
BMC Res Notes. 2011 Feb 09;4:35
pubmed: 21303563
BMC Res Notes. 2015 Dec 01;8:737
pubmed: 26625733
Am J Trop Med Hyg. 2011 Aug;85(2):390-4
pubmed: 21813864
AIDS. 2008 Jun 19;22(10):1221-2
pubmed: 18525268
AIDS Res Ther. 2016 Feb 04;13:6
pubmed: 26855663
World J Hepatol. 2012 Mar 27;4(3):74-80
pubmed: 22489259
BMC Public Health. 2002 Nov 22;2:26
pubmed: 12445329
Biomed Res Int. 2018 Jan 2;2018:9241679
pubmed: 29487874
PLoS One. 2014 Feb 26;9(2):e90194
pubmed: 24587275
Hepatology. 2009 May;49(5 Suppl):S138-45
pubmed: 19399813
AIDS Res Treat. 2014;2014:581021
pubmed: 25580287
J Med Microbiol. 2014 May;63(Pt 5):742-7
pubmed: 24757219
Afr Health Sci. 2009 Jun;9(2):98-108
pubmed: 19652743
Can J Infect Dis Med Microbiol. 2014 Spring;25(1):e8-e13
pubmed: 24634693
Hepat Res Treat. 2016;2016:9290163
pubmed: 26904281